Opportunistic Infections and HIV

Opportunistic Infections Risk Factors

Prophylaxis Options for Opportunistic Infections for sulfa allergy

Prophylaxis Options for Opportunistic Infections for G6PD deficiency

Pneumocystis jirovecii pneumonia

Critiera for starting, primary prophylaxis regimen, criteria for discontinuing)

Toxoplasma gondii encephalitis

Criteria for starting, primary prophylaxis regimen, criteria for discontinuing)

Mycobacterium avium complex (MAC)

Criteria for starting, primary prophylaxis regimen, criteria for discontinuing)

Formulation preference for thrush in patients with HIV

Candidiasis (oropharyngeal/esophageal)

Preferred regimen, alternative regimen, secondary prophylaxis

Cryptococcal meningitis

Preferred regimen, alternative regimen

Cytomegalovirus

Preferred regimen, alternative regimen

Mycobacterium avium complex

Preferred regimen

Pneumocystis jirovecii pneumonia

Preferred regimen, alternative regimen

Toxoplasma gondii encephalitis

Risk of infection, Preferred regimen

AIDS diagnosis

Routine lab tests for HIV

Preferred Initial ART Regimens in Most Treatment Naive Adults - Single Tablet Regimen

Preferred Initial ART Regimens in Most Treatment Naive Adults - Two Tablet Regimen

Preferred Initial ART Regimens in Most Treatment Naive Adults - Comments

Alternative ART Regimens

ART Regimen Recommendations for Treatment Naive Pregnant Patients

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

MOA, dosing frequency, renal, zidovudine

Key features and safety issues: all NRTIs, Abacavir, Emtricitabine, Tenofovir Formulations, Zidovudine

Integrase Strand Transfer Inhibitors (INSTIs)

MOA, dosing frequency, renal, Cabotegravir ER IM

Key features and safety issues: all INSTIs, Bictegravir and dolutegravir, Raltegravir and dolutegravir, Dolutegravir, Cabotegravir IM, Drug Interactions

Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Administration: rilpivirine, efavirenz

Key features and safety issues: All NNRTI, Efavirenz, Rilpivirine Drug Interactions

Protease Inhibitors (PIs)

Administration: all, atazanavir

Key features and safety issues: All PIs, Darunavir, Lopinavir/Ritonavir, Atazanavir

Pharmacokinetic Boosters (Enhancers)

Drugs, Administration, Key Features

PI and PK Booster Drug Interactions

CCR5 Antagonist

MOA, Baseline test required

Attachment Inhibitor

Name

Post-Attachment Inhibitor

Name, Formulation

Combination regimens: INSTI-based

Biktarvy, Cabenuva, Triumeq, Dovato, Stribild, Genvoya

Notes: Biktarvy and Dovato, Cabenuva, renal, Stribild and Genvoya

Combination regimens: NNRTI-based

Delstrigo, Complera, Odefsey

Combination regimens: PI-based

Symtuza

Combination regimens: NRTI-based

Descovy, Truvada

Notes: renal